Skip to main content
Donate

Research

Fast Funding

ATFs 2.0: UBE3A Activation without SNORD Inhibition

$103,235 2019 FT2019-002

ATFs 2.0: UBE3A Activation without SNORD Inhibition

Dr. Segal’s past work on artificial transcription factors (ATFs) showed global paternal gene activation after subcutaneous injection. In bringing this therapeutic platform to the next level for human use it was prudent to evaluate options to find a mechanism of ensuring that we do not inhibit the SNORD116 and SNORD115 RNAs, which are associated with Prader-Willi syndrome. This proposal is to build on the capabilities of epigenetic editing and brain delivery seeking new targeting strategies to protect SNORD116.

Principle Investigator

Dave Segal, PhD

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.